AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the…
AbCellera announced that LY-CoV555, a human antibody discovered by AbCellera in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research…
Read More...
Read More...
